Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

BACKGROUND: Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Am Heart Assoc
Auteurs principaux: Magnani, Giulia, Bonaca, Marc P., Braunwald, Eugene, Dalby, Anthony J., Fox, Keith A. A., Murphy, Sabina A., Nicolau, José Carlos, Oude Ophuis, Ton, Scirica, Benjamin M., Spinar, Jindrich, Theroux, Pierre, Morrow, David A.
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2015
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4392433/
https://ncbi.nlm.nih.gov/pubmed/25792124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001505
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires